Cv Sciences outlines CMS program allowing up to $500 annually in hemp-derived products as it targets positive cash flow in H2 2026
Source: SeekingAlpha
2026-05-14 18:51:52 ET
More on CV Sciences
- CV Sciences, Inc. (CVSI) Q1 2026 Earnings Call Prepared Remarks Transcript
- CV Sciences, Inc. (CVSI) Q4 2025 Earnings Call Prepared Remarks Transcript
- CV Sciences GAAP EPS of $0.00, revenue of $3.2M
- CV Sciences outlines non-cannabinoid product launches and margin gains as company targets cash flow breakeven through 2026
- Historical earnings data for CV Sciences
Read the full article on Seeking Alpha
For further details see:
Cv Sciences outlines CMS program allowing up to $500 annually in hemp-derived products as it targets positive cash flow in H2 2026
CV Sciences Inc.
NASDAQ: CVSI
CVSI Trading
-10.0% G/L:
$0.018 Last:
528,130 Volume:
$0.0184 Open:
CVSI Latest News
June 25, 2026 08:00:00 pm
CV Sciences Expands +PlusHLTH(TM) Portfolio with Personalized Wellness Solutions for Healthy Aging
$6,817,756
177,261,643
0.54%
5
N/A
Pharmaceuticals
Healthcare
US
San Diego
